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This daily COVID-19 Health Evidence Summary is to signpost DFID and other UK government 
departments to the latest relevant evidence and discourse on COVID-19 to inform and support 
their response. It is a result of 3 hours of work and is not intended to be a comprehensive summary 
of available evidence on COVID-19 but aims to make original documents easily accessible to 
decision makers which, if relevant to them, they should go to before making decisions.   
 
Clinical characteristics and management 
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
25.05.20 Management of 
mild COVID-19: 
Policy 
implications of 
initial 
experience in 
India 
medRxiv| 
preprint (not 
peer 
reviewed) 
 Study aimed at describing clinical 
characteristics and outcomes of 
admitted patients with mild COVID-19 
illness in the initial phase of pandemic 
in India. 
 Conclusions - Patients with mild 
disease at presentation had a stable 
disease course and therefore such 
cases can be managed outside 
hospital setting. 
Infection Prevention and Control 
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
  
25.05.20 Coronavirus 
(COVID-19) 
infection in 
children at a 
specialist 
centre: 
medRxiv| 
preprint (not 
peer 
reviewed) 
 There is evolving evidence of significant 
differences in severity and outcomes of 
COVID-19 in children compared to 
adults. 
 In children presenting with pre-existing 
COVID-19 vulnerable medical conditions 
at a specialist centre, there does not 
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outcome and 
implications of 
underlying 
high-risk 
comorbidities in 
a paediatric 
population 
appear to be significantly increased risk 
of either contracting COVID-19 or severe 
complications, apart from those 
undergoing chemotherapy, who are 
over-represented. 
Therapeutics 
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
22.05.20 Remdesivir 
for the 
Treatment of 
Covid-19 — 
Preliminary 
Report 
New England 
Journal of 
Medicine|Article 
 A trial of the drug remdesivir showed 
that it shortens the recovery of people 
hospitalized for COVID-19.  
 John Beigel at the National Institutes 
of Allergy and Infectious Diseases in 
Rockville, Maryland, and his 
colleagues studied more than 1,000 
people enrolled in a randomized, 
double- blind trial and found that 
those who took remdesivir had a 
median recovery time of 11 days, 
compared to 15 days for those who 
took a placebo. 
Social Science 
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
21.05.20 Public 
knowledge, 
attitudes and 
practices 
towards 
COVID-19: A 
cross-
sectional 
study in 
Malaysia 
PLOS ONE | 
Research 
article 
 Cross-sectional online survey of 4,850 
Malaysian residents was conducted 
between 27th March-3rd April 2020. 
 Respondents largely positive about 
way government was handling COVID-
19. Most avoiding crowds and washing 
hands but fewer wearing masks. 
 The results highlight the importance of 
consistent messaging from health 
authorities and the government as well 
as the need for tailored health 
education programs to improve levels 
of knowledge, attitudes and practices. 
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Comments, Editorials, Opinions, Blogs, News 
Publication 
date 
Title/URL Journal | Article type Author(s) 
22.05.20 Hydroxychloroquine prophylaxis 
for high-risk COVID-19 contacts 
in India: a prudent approach 
Lancet/  Correspondence Praveen Tilangi, 
Devashish Desai, 
Adil Khan, 
Manish Soneja 
21.05.20 Detection of SARS-CoV-2 in 
human breastmilk  
Lancet/  Correspondence Rüdiger Groß 
Carina 
Conzelmann et 
al. 
  
1.06.20 Food insecurity will be the sting 
in the tail of COVID-19 
Lancet Global Health/ 
Editorial 
  
26.05.20 Invest in planetary health to build 
resilience, urges global health 
community 
UK Health Alliance on 
Climate Change’ 
  
25.05.20 Trump’s favoured drug shows no 
benefit — but another drug does 
Nature / News   
22.05.20 Translating Science on COVID-
19 to Improve Clinical Care and 
Support the Public Health 
Response 
JAMA / Viewpoint Carlos del Rio, 
Preeti Malani, 
26.05.20 0.27% Rise in Infections Pushes 
Total of African COVID-19 
Cases Over 115,000 
All Africa / News   
26.05.20 Rwanda: COVID-19 - 
Researchers Discover New 
Method of Mass Testing 
All Africa / News   
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Guidelines, Statements & Tools 
Publication 
Date 
Title/URL Source   Summary 
 22.05.2020 Framework for 
decision-making: 
implementation of 
mass vaccination 
campaigns in the 
context of COVID-19 
WHO | 
Interim 
Guidance 
  Outlines a common framework for 
decision-making for the conduct of 
preventive and outbreak response 
campaigns 
 Considerations for implementing 
mass vaccination campaigns for 
prevention of increased risk of 
vaccine-preventable diseases 
(VPD)/high impact diseases (HID) 
among susceptible populations 
 Details the risks and benefits of 
conducting vaccination campaigns to 
respond to VPD/HID outbreaks 
Dashboards & Trackers 
Cases & 
deaths: 
Global 
Cases & 
deaths: 
Regional 
Cases & 
deaths: 
Country 
Living 
evidence 
& policy 
maps 
Current 
research 
including trials 
  Diagnosti
cs 
  Treatment
s 
  Vaccin
es 
WHO 
sitreps 
WHO 
Africa 
Ghana COVID-
NMA 
WHO   FIND 
SARS-
CoV-2 Test 
Tracker 
  Global 
COVID-19 
Clinical 
Trial 
Tracker 
  CEPI 
WHO 
dashboard 
African 
Argumen
ts 
Indonesi
a 
EPPI 
Centre 
WHO 
International 
Clinical Trials 
Registry 
Platform 
(ICTRP) 
 FIND 
SARS-
CoV-2 
Diagnostic
s: 
performanc
e data 
  US NIH 
registered 
clinical 
trials 
Vaccine 
Centre 
LSHTM 
Johns 
Hopkins 
University 
Europea
n CDC 
Nigeria 
CDC 
Norwegian 
Institute of 
Public 
Health 
Cytel  Serology-
based 
tests for 
COVID-19 
  Solidarity 
trial 
 COVID-
19 
Oxford 
Vaccine 
Trial 
5 
WEF 
  Sierra 
Leone 
 Oxford 
C19 
Governme
nt 
Response 
Tracker 
(OxCGRT) 
US NIH  Our World 
in Data: 
C19 
Testing 
  COVID-
19 
Therapeuti
cs 
Accelerator 
  
Our World 
in Data 
  Singapor
e 
 Our World 
in Data: 
C19 Policy 
responses 
COVID-
evidence 
      
Global 
5050 
  UK  IFPRI 
COVID-19 
Policy 
Response 
Portal 
Cochrane       
CEBM, 
University 
of Oxford 
  US   Clinicaltrials.g
ov 
      
Humanitari
an Data 
Exchange 
       UKCDR       
Information 
is Beautiful 
              
LSHTM               
HealthMap 
(cases) 
              
The 
Commons 
Project 
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C19 Resource Hubs 
Global  Region
al & 
Country 
Academi
c journals 
& 
Publisher
s 
Institutes/Centres/Funders/O
ther 
Health 
Topics 
  Social 
Sciences 
WHO COVID-
19 pandemic  
Africa 
CDC 
Annals of 
Internal 
Medicine 
LSTM Stop TB 
Partnership 
  SSHAP 
WHO risk 
communicatio
n 
African 
Union 
BMJ LSHTM 
 
  IDA 
WHO Q&A Nigeria 
CDC 
Bulletin 
of the 
WHO 
ICL MRC Centre for Global 
Infectious Disease Analysis  
Global 
Menstrual 
Collective  
  Disability 
and 
inclusion 
WHO Global 
research 
GeoPoll
: SSA 
Cambridg
e 
Universit
y Press 
ODI SLH: 
Handwashi
ng in low 
resource 
settings 
  Coregrou
p IDDC 
COVID-19 
Solidarity 
Response 
Fund 
Global 
Health 
Network 
Africa 
Cell 
Press 
Johns Hopkins University RBM 
Partnership 
  Ethics, 
health 
systems & 
COVID-19 
UN African 
Academ
y of 
Science
s 
Cochrane  Center for Global 
Development 
    Social 
Developme
nt Direct 
C19 blog 
series 
UN Women Africa 
Evidenc
e 
Network 
Elsevier CMMID Repository     
7 
UNOCHA OCHA 
Souther
n and 
Eastern 
Africa 
COVID-
19 
Digest 
JAMA 
Network 
Norwegian Institute of Public 
Health 
    
UNHCR   The 
Lancet 
Oxford Centre for Evidence-
based Medicine 
    
UNICEF   medRxiv 
and 
bioRxiv 
(Preprints
) 
 HEART     
UNESCO   NEJM  UKRI     
UN WFP   Oxford 
Universit
y Press 
 Evidence Aid     
GOARN   PLoS  NIH     
EPI-WIN   SAGE 
journals 
IFPRI Resources and 
Analyses of C19 Impact 
    
World Bank   Science  Prevent Epidemics      
Our World in 
Data 
  Springer 
Nature 
      
COVID-19 
Narratives by 
David 
Nabarro 
  SSRN 
(Preprints
)  
      
Reliefweb   Wiley       
8 
Humanitarian 
OpenStreetM
ap Team 
          
Global 
Partnership 
for 
Sustainable 
Development 
Data 
  
 
      
WorldPop           
Flowminder           
COVID-END           
Premise 
COVID-19 
Global Impact 
Study 
    
  
Online learning & events 
Date Title/URL Online 
learning/event 
Duration Lead 
04.06.2020 
12pm ET 
CGD Conversations 
on COVID-19 and 
Development: John 
Nkengasong 
Event   CGD 
Available 
now 
WHO Academy and 
WHO Info mobile 
applications 
Mobile app   WHO 
Available 
now 
COVID-19: 
Pandemics, Modelling 
and Policy 
Online 
learning 
2 weeks | 2 
hours 
weekly 
study 
FutureLearn UNESCO 
UNITWIN Complex 
Systems Digital 
Campus/Open 
University 
9 
11.5.2020 COVID-19 Contact 
Tracing course 
Online 
learning 
5 hours Johns Hopkins 
Bloomberg School of 
Health 
7-28 May 
2020 
Virtual Evidence 
Weeks 
5 sessions 1h 30 International Initiative 
for Impact Evaluation 
(3ie) 
Tuesdays at 
1700 CEST 
(Geneva 
time) & 
Thursdays 
0830 CEST 
(Geneva 
time) 
COVID-19 Open 
online brief with Dr 
David Nabarro 
Event 1h 4SD 
30.04.2020 Professor Chris 
Whitty’s Gresham 
lecture on COVID-19 
Event 1h 20 Gresham College 
Available 
now 
Emerging respiratory 
viruses, including 
COVID-19: methods 
for detection, 
prevention, response 
and control 
Online 
learning 
3 hours WHO 
Available 
now 
Responding to 
COVID-19: Real-time 
training for the 
coronavirus disease 
outbreak 
Online 
learning 
Multiple 
self-paced 
course 
WHO 
25 May 
2020 
COVID-19: Tackling 
the Novel Coronavirus 
Online 
learning 
3 weeks | 4 
hours 
weekly 
study 
FutureLearn 
LSHTM/UK PHRST 
Available 
online now 
without 
mentors. 
Updated 
COVID-19 
Diagnostics and 
Testing 
Online 
learning 
3 weeks | 3 
hours 
weekly 
study 
FutureLearn 
FIND/LSHTM/ASLM 
10 
version will 
commence 
early June 
2020 
6 April 2020 COVID-19 Critical 
Care: Understanding 
and Application 
Online 
learning 
5 weeks | 1 
hour 
weekly 
study 
FutureLearn University 
of Edinburgh & Royal 
College of Physicians 
of Edinburgh  
Available 
now 
COVID-19 supporting 
online courses 
Online 
learning 
Multiple 
self-paced 
course 
BMJ Learning 
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Rapid review methodology 
The rapid daily search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa”) OR (“equity” OR “equities”) OR (“poverty”), restricted to 
articles published in the previous 2 to 3 days, in English. This is complemented by a search of the homepage of 
the following high-impact global health journals: The Lancet journals, New England Journal of Medicine, Nature, 
JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ Global Health, the PLoS journals and a Twitter 
search of their Twitter pages. A search also of preprints from bioRxiv and medRxiv. Please note that papers that 
have not been peer-reviewed are highlighted in red. All primary research papers that relate to the primary and 
secondary impacts of the COVID-19 response in LMICs, and disease control and health system responses are 
included. Articles related to tackling the secondary impacts on other sectors are not included. Additional 
commentaries, opinions, and commissioned pieces are selected based on relevance. 
The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
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About this report 
This daily COVID-19 health evidence summary (HES) is based on 3 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before 
making decisions. The HES are not intended to replace medical or professional advice and the researcher or the 
K4D consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES 
alone. K4D services are provided by a consortium of leading organisations working in international development, 
led by the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds 
Nuffield Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), 
University of Birmingham International Development Department (IDD) and the University of Manchester 
Humanitarian and Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Department for 
International Development (DFID) and its partners in support of pro-poor programmes. 
It is licensed for non-commercial purposes only. K4D cannot be held responsible for 
errors, omissions or any consequences arising from the use of information contained in 
this health evidence summary. Any views and opinions expressed do not necessarily 
reflect those of DFID, K4D or any other contributing organisation.  
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